Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

@article{Baek2011PrognosticFI,
  title={Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.},
  author={Kyung Kee Baek and Jung-Hoon Kim and Ji Eun Uhm and Se Hoon Park and Jeeyun Lee and Joon Oh Park and Yong Seog Park and Won Ki Kang and Ho-yeong Lim},
  journal={Oncology},
  year={2011},
  volume={80 3-4},
  pages={167-74}
}
BACKGROUND Sorafenib, a multitargeted tyrosine kinase inhibitor, is now the treatment of choice for systemic therapy of patients with advanced hepatocellular carcinoma (HCC). Herein, we present the clinical characteristics and outcomes of patients with advanced HCC who were treated with sorafenib. METHODS Data of 201 sorafenib-treated, metastatic HCC patients were collected from a single institution tumor registry. The primary and secondary endpoints were overall survival (OS) and failure… CONTINUE READING
21 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…